NRD
AVIR icon

Nebula Research & Development’s Atea Pharmaceuticals AVIR Stock Holding History

Nebula Research & Development’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-97,107
Closed -$363K – 490
2023
Q2 		$363K Buy
+97,107
New +$364K 0.28% 186

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's AVIR Position: Q3 2023 in Review

Nebula Research & Development sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 97,107 shares — an estimated $363K sold.

Nebula Research & Development first reported a position in AVIR in Q2 2023 and held it in 1 quarter. The position peaked at $363K in Q2 2023. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • Nebula Research & Development reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 97,107 Atea Pharmaceuticals shares in Q3 2023, an estimated $363K.
  • Nebula Research & Development first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's Atea Pharmaceuticals position peaked at $363K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.